Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia Trial

Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia (4P) ¿ a randomised, placebo-controlled, double-blind clinical trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201311000700893

Enrollment

440

Registered

2013-11-08

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Pregnancy and Childbirth Hypertensive disorders in pregnancy, pregnancy-induced hypertension, preeclampsia

Interventions

Polypill

Placebo

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: - 20%) of developing PIH

Exclusion criteria

Exclusion criteria: - Pre-existing hypertension or hypertension before 20 weeks gestation. - Likely non-compliance with the protocol in view of the treating physician - Comorbidity interfering with the protocol - Known contraindications to Investigational Product components

Design outcomes

Primary

Measure	Time frame
Pregnancy-induced hypertension	—

Secondary

Measure	Time frame
Maternal/obstetric outcomes: maternal death, preeclampsia, eclampsia, HELLP syndrome, hemorrhage, saesarian section, other complications during pregnancy or delivery;Neonatal and infant outcomes: preterm birth, Intra uterine death, stillbirth, neonatal mortality, congenitial abnormality, NICU admission or pediatrician referral, birth weight, small for gestational age, apgar scores, other adverse effects. Infant outcomes: weight and hight, health, occurrence of disease and general health status. ;Tertiary: uptake and tolerability	—

Measure

Time frame

Maternal/obstetric outcomes: maternal death, preeclampsia, eclampsia, HELLP syndrome, hemorrhage, saesarian section, other complications during pregnancy or delivery;Neonatal and infant outcomes: preterm birth, Intra uterine death, stillbirth, neonatal mortality, congenitial abnormality, NICU admission or pediatrician referral, birth weight, small for gestational age, apgar scores, other adverse effects. Infant outcomes: weight and hight, health, occurrence of disease and general health status. ;Tertiary: uptake and tolerability

—

Countries

Ghana

Contacts

Public ContactJoyce Browne

Coordinating Investigator

J.L.Browne@umcutrecht.nl+31649650071

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026